Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed colon or rectal cancer
• * Metastatic or unresectable disease
• Unidimensionally measurable disease required for phase II only
• * At least 20 mm by x-ray, CT scan, MRI, or photography
• * The following are not considered measurable:
• * Pleural effusion or ascites
• * Osteoblastic lesions
• * Evidence of disease on bone scan alone
• * Progressive irradiated lesions alone
• * Bone marrow involvement
• * Brain metastases
• * Malignant hepatomegaly by physical exam alone
• * Chemical markers (e.g., carcinoembryonic antigen)
• * Recurrent disease after surgery or radiotherapy is considered measurable as long as the following criteria are met:
• * At least 4 weeks since prior surgery or radiotherapy
• * Measurable disease exists outside the radiation port or clear progression exists within the radiation port
• Tissue accessible for immunohistochemical evidence of epidermal growth factor receptor expression from a metastatic site (phase II only)
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy
• More than 3 months
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin normal
• AST/ALT no greater than 2.5 times upper limit of normal
• Renal
• Creatinine normal OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular
• No unstable angina pectoris
• No symptomatic congestive heart failure
• No cardiac arrhythmia
• No uncontrolled hypertension (systolic blood pressure greater than 150 mm Hg)
• Opthalmic
• No abnormalities of the cornea (e.g., severe dry eye syndrome or Sjogren's syndrome)
• No congenital abnormality (e.g., Fuch's dystrophy)
• No abnormal slit-lamp examination using vital dye (e.g., fluorescein or Bengal-Rose)
• No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear-production test)
• Mild dry eye syndrome allowed if patient can use artificial tears and ophthalmologist concurs
• Gastrointestinal
• No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• No active peptic ulcer disease
• Other
• Must be able and willing to undergo a mediport insertion
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancy within the past 5 years except previously excised and inactive basal cell or squamous cell skin cancer
• No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib or other study drugs (e.g., epidermal growth factor inhibitors like cetuximab)
• No significant traumatic injury within the past 3 weeks
• No peripheral neuropathy grade 2 or greater
• No ongoing or active infection
• No other uncontrolled concurrent illness that would preclude study entry
• No psychiatric illness or social situation that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Phase I:
• * Prior chemotherapy allowed
• Phase II:
• * No prior chemotherapy for metastatic disease
• * Prior adjuvant therapy allowed if disease progresses during adjuvant therapy
• * No prior oxaliplatin
• Endocrine therapy
• Not specified
• Radiotherapy
• See Disease Characteristics
• More than 4 weeks since prior radiotherapy and recovered
• Surgery
• See Disease Characteristics
• More than 3 weeks since prior major surgery and recovered
• No prior surgical procedures affecting absorption
• Other
• No other concurrent investigational agents
• No other concurrent anticancer agents or therapies (commercial or investigational)
• No concurrent combination antiretroviral therapy for HIV-positive patients